[Bladder cancer and malignant melanoma following Endoxan therapy of a lymphoproliferative disease].
D000236:Adenoma / Q000139:chemically induced; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced*; D002584:Cervix Uteri / Q000139:chemically induced / Q000473:pathology; D003520:Cyclophosphamide / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007943:Leukemia, Hairy Cell / Q000188:drug therapy*; D008545:Melanoma / Q000139:chemically induced*; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000139:chemically induced*; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced*; D002583:Uterine Cervical Neoplasms / Q000139:chemically induced
D003520:Cyclophosphamide; D011241:Prednisone
Blasenkarzinom und malignes Melanom nach langjäriger Endoxan-Therapie einer lymphoproliferativen Krankheit.